Bioverativ (NASDAQ:BIVV) had its price target boosted by Jefferies Group to $79.00 in a research report sent to investors on Thursday, January 18th, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also recently commented on BIVV. Argus raised shares of Bioverativ from a hold rating to a buy rating and set a $64.00 target price on the stock in a research report on Wednesday, September 20th. Morgan Stanley reissued an underweight rating and set a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Zacks Investment Research raised shares of Bioverativ from a hold rating to a strong-buy rating and set a $69.00 price target on the stock in a research report on Thursday, October 19th. Piper Jaffray Companies reissued an overweight rating and set a $71.00 price target on shares of Bioverativ in a research report on Monday, October 23rd. Finally, Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the stock a hold rating in a research report on Monday, November 20th. Thirteen research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $63.15.
Bioverativ (BIVV) opened at $103.60 on Thursday. Bioverativ has a 1 year low of $43.19 and a 1 year high of $104.30.
A number of large investors have recently modified their holdings of BIVV. Wells Fargo & Company MN acquired a new stake in Bioverativ in the third quarter valued at approximately $124,500,000. Woodford Investment Management Ltd acquired a new stake in Bioverativ in the third quarter valued at approximately $85,455,000. Jackson Square Partners LLC acquired a new stake in Bioverativ in the third quarter valued at approximately $99,336,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ in the third quarter valued at approximately $96,827,000. Finally, BlackRock Inc. raised its holdings in Bioverativ by 16.9% in the fourth quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after acquiring an additional 1,567,638 shares in the last quarter. 94.10% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/bioverativ-bivv-price-target-raised-to-79-00.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.